Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2011, Article ID 640284, 8 pages
http://dx.doi.org/10.1093/ecam/nep136
Review Article

A Systematic Review of Single Chinese Herbs for Alzheimer's Disease Treatment

Department of Western Medicine, Southern California University of Health Sciences, Whittier, CA 90604, USA

Received 3 February 2009; Accepted 8 July 2009

Copyright © 2011 Li-Min Fu and Ju-Tzu Li. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Burns, E. J. Byrne, and K. Maurer, “Alzheimer's disease,” The Lancet, vol. 360, no. 9327, pp. 163–165, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. D. A. Evans, H. H. Funkenstein, M. S. Albert et al., “Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported,” Journal of the American Medical Association, vol. 262, no. 18, pp. 2551–2556, 1989. View at Google Scholar · View at Scopus
  3. L. E. Hebert, P. A. Scherr, J. L. Bienias, D. A. Bennett, and D. A. Evans, “Alzheimer disease in the US population: prevalence estimates using the 2000 census,” Archives of Neurology, vol. 60, no. 8, pp. 1119–1122, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Tiraboschi, L. A. Hansen, L. J. Thal, and J. Corey-Bloom, “The importance of neuritic plaques and tangles to the development and evolution of AD,” Neurology, vol. 62, no. 11, pp. 1984–1989, 2004. View at Google Scholar · View at Scopus
  5. G. L. Wenk, “Neuropathologic changes in Alzheimer's disease,” Journal of Clinical Psychiatry, vol. 64, no. 9, pp. 7–10, 2003. View at Google Scholar · View at Scopus
  6. C. Schmitz, B. P. F. Rutten, A. Pielen et al., “Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease,” American Journal of Pathology, vol. 164, no. 4, pp. 1495–1502, 2004. View at Google Scholar · View at Scopus
  7. C. Holmes, D. Boche, D. Wilkinson et al., “Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial,” The Lancet, vol. 372, no. 9634, pp. 216–223, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. P. T. Francis, A. M. Palmer, M. Snape, and G. K. Wilcock, “The cholinergic hypothesis of Alzheimer's disease: a review of progress,” Journal of Neurology Neurosurgery and Psychiatry, vol. 66, no. 2, pp. 137–147, 1999. View at Google Scholar · View at Scopus
  9. S. Salloway, S. Ferris, A. Kluger et al., “Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial,” Neurology, vol. 63, no. 4, pp. 651–657, 2004. View at Google Scholar · View at Scopus
  10. S. Akhondzadeh and S. H. Abbasi, “Herbal medicine in the treatment of Alzhelmer's disease,” American Journal of Alzheimer's Disease and other Dementias, vol. 21, no. 2, pp. 113–118, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. L. L. D. Santos-Neto, M. A. de Vilhena Toledo, P. Medeiros-Souza, and G. A. De Souza, “The use of herbal medicine in Alzheimer's disease—a systematic review,” Evidence-Based Complementary and Alternative Medicine, vol. 3, no. 4, pp. 441–445, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. S. C. Man, S. S. K. Durairajan, W. F. Kum et al., “Systematic review on the efficacy and safety of herbal medicines for Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 14, no. 2, pp. 209–223, 2008. View at Google Scholar · View at Scopus
  13. A. R. Jadad, R. A. Moore, D. Carroll et al., “Assessing the quality of reports of randomized clinical trials: is blinding necessary?” Controlled Clinical Trials, vol. 17, no. 1, pp. 1–12, 1996. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Maurer, R. Ihl, T. Dierks, and L. Frölich, “Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type,” Journal of Psychiatric Research, vol. 31, no. 6, pp. 645–655, 1997. View at Publisher · View at Google Scholar · View at Scopus
  15. L. S. Schneider, S. T. DeKosky, M. R. Farlow, P. N. Tariot, R. Hoerr, and M. Kieser, “A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type,” Current Alzheimer Research, vol. 2, no. 5, pp. 541–551, 2005. View at Google Scholar · View at Scopus
  16. M. Mazza, A. Capuano, P. Bria, and S. Mazza, “Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study,” European Journal of Neurology, vol. 13, no. 9, pp. 981–985, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. S.-S. Xu, Z.-X. Gao, Z. Weng et al., “Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease,” Acta Pharmacologica Sinica, vol. 16, no. 5, pp. 391–395, 1995. View at Google Scholar · View at Scopus
  18. Z. Zhang, X. Wang, Q. Chen, L. Shu, J. Wang, and G. Shan, “Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial,” Zhonghua yi xue za zhi, vol. 82, no. 14, pp. 941–944, 2002. View at Google Scholar · View at Scopus
  19. J.-H. Heo, S.-T. Lee, K. Chu et al., “An open-label trial of Korean red ginseng as an adjuvant treatment for cognitive impairment in patients with Alzheimer's disease,” European Journal of Neurology, vol. 15, no. 8, pp. 865–868, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Ramassamy, F. Longpré, and Y. Christen, “Ginkgo biloba extract (EGb 761) in Alzheimer's disease: is there any evidence?” Current Alzheimer Research, vol. 4, no. 3, pp. 253–262, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Wang and C. T. Xi, “Neuroprotective effects of huperzine A: a natural cholinesterase inhibitor for the treatment of Alzheimer's disease,” NeuroSignals, vol. 14, no. 1-2, pp. 71–82, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Y. Zhang and X. C. Tang, “Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease,” Trends in Pharmacological Sciences, vol. 27, no. 12, pp. 619–625, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Fujiwara, K. Iwasaki, K. Furukawa et al., “Uncaria rhynchophylla, a Chinese medicinal herb, has potent antiaggregation effects on Alzheimer's β-amyloid proteins,” Journal of Neuroscience Research, vol. 84, no. 2, pp. 427–433, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Jia, Y. Jiang, Y. Ruan et al., “Tenuigenin treatment decreases secretion of the Alzheimer's disease amyloid β-protein in cultured cells,” Neuroscience Letters, vol. 367, no. 1, pp. 123–128, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. D. K. Kim, K. T. Lee, N. I. Baek et al., “Acetylcholinesterase inhibitors from the aerial parts of Corydalis speciosa,” Archives of Pharmacal Research, vol. 27, no. 11, pp. 1127–1131, 2004. View at Google Scholar · View at Scopus
  26. M. Asai, N. Iwata, A. Yoshikawa et al., “Berberine alters the processing of Alzheimer's amyloid precursor protein to decrease Aβ secretion,” Biochemical and Biophysical Research Communications, vol. 352, no. 2, pp. 498–502, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Leclerc, M. Garnier, R. Hoessel et al., “Indirubins inhibit glycogen synthase kinase-3β and CDK5/P25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?” Journal of Biological Chemistry, vol. 276, no. 1, pp. 251–260, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. F. Chen, E. A. Eckman, and C. B. Eckman, “Reductions in levels of the Alzheimer's amyloid beta peptide after oral administration of ginsenosides,” The FASEB Journal, vol. 20, no. 8, pp. 1269–1271, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Li, H. M. Wu, R. L. Zhou, G. J. Liu, and B. R. Dong, “Huperzine A for Alzheimer's disease,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD005592, 2008. View at Google Scholar · View at Scopus
  30. E. Kolibas, V. Korinkova, V. Novotny, K. Vajdickova, and D. Hunakova, “ADAS-cog (Alzheimer's Disease Assessment Scale-cognitive subscale)–validation of the Slovak version,” Bratislavske Lekarske Listy, vol. 101, no. 11, pp. 598–602, 2000. View at Google Scholar · View at Scopus
  31. D. S. H. L. Kim, J.-Y. Kim, and Y. S. Han, “Alzheimer's disease drug discovery from herbs: neuroprotectivity from β-amyloid (1-42) insult,” Journal of Alternative and Complementary Medicine, vol. 13, no. 3, pp. 333–340, 2007. View at Publisher · View at Google Scholar · View at Scopus